Summarized by Masters of Longevity from Longevity Docs News.
ZEUS found no reduction in heart attack, stroke, or cardiovascular death despite large hs-CRP lowering.
Key Takeaways
- Ziltivekimab lowered hs-CRP but did not reduce events.
- The trial enrolled adults with atherosclerosis and kidney disease.
- The study showed more serious infections and competing deaths.
